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Vagus nerve stimulation (VNS) received approval for medical
use by the European authorities in 1994 and by the US Food and
Drug Administration in 1997. Today, about ﬁfteen years later, VNS
may fairly be regarded as the third pillar of epilepsy treatment,
besides antiepileptic drugs (AEDs) and epilepsy surgery.1 More
than 60,000 stimulators had been implanted for the treatment of
epilepsy by November 2011 (Cyberonics Inc., personal communi-
cation) and an increasing number of patients are now getting re-
implanted after battery-end-of-service of the pulse generator. In
Germany, VNS treatment is completely reimbursed by the public
health insurance, including the cost for devices, implantation
surgery, all necessary follow-up visits, and re-implantations.
However, the local budgets at epilepsy centres and thus the
number of affordable devices per year is limited and re-
implantations have to be scheduled within this budget.
But is there compelling evidence for the clinical effectiveness of
VNS?
In this edition of Seizure Garcı´a-Navarrete et al. report 18-
months follow-up data from a sample of patients treated with VNS
and stable AEDs.2 The authors report that 27/43 patients (63%)
experienced a greater than 50% reduction of their monthly seizure
frequency (seizure responders). This ﬁnding is completely in line
with the great number of reports on VNS from the last 15 years1
including a similar study on patients receiving unchanged
medication by Labar.3 Based on this evidence, Garcı´a-Navarrete
et al. conclude that VNS is an ‘‘effective therapy in the long-term
control of medication-resistant seizures’’. I have some serious
concerns about this conclusion, and this editorial comment is
motivated by the observation that this new paper is rather
symptomatic of the entire VNS literature.
First, the outcome was not entirely positive. The device had to
be explanted or switched off in 5/43 implanted patients (12%) for
different reasons (e.g. infection); the treatment was ineffective in
11/43 patients (26%, non-responders); no patient experienced
complete and sustained release from seizures; and side-effects
were reported by 22/43 patients (51%), including such severe
adverse effects as dysphagia in one instance. Again, this dataset
resembles the ﬁndings of former studies.1 Taken together, VNS
realistically offers odds of roughly 50:50 for the individual patient
to experience a moderate (but most probably not substantial)
improvement of seizure status. This means that every other VNS
patient cannot be expected to experience any therapeutic beneﬁt.
Nevertheless, the patient has to bear the complete burden of
surgical risks, often irreversible diagnostic limitations (such as
reduced feasibility of high-ﬁeld magnetic resonance imaging),
and stimulation-related adverse effects. From a medico-ethicalDOI of original article: http://dx.doi.org/10.1016/j.seizure.2012.09.008
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.10.001perspective, an elective invasive treatment with a partly irrevers-
ible burden for the patient and such a high probability of treatment
failure hardly appears recommendable, or even justiﬁable.
Second, Garcı´a-Navarrete et al. were not in the position to draw
any conclusion about the efﬁcacy of VNS from their data. For logical
reasons, single-arm studies do generally not support causal
attribution of changes occurring over time to a given medical
intervention, especially not to one particular part of a more
complex treatment package. Obviously, things are always chang-
ing and more likely to improve if they were particularly
unsatisfactory when the treatment was applied (regression toward
the mean). In contrast to many other studies, Garcı´a-Navarrete
et al.2 managed to exclude medication changes as a confounding
factor, but this does not satisfy the logical requirement of a control
group for the evaluation of the effectiveness of an intervention.
Unfortunately, adequately controlled studies on VNS are
lacking. This does not stop the authors of countless single-arm
studies from drawing positive conclusions about the efﬁcacy of
VNS from their data which is, of course, a logical fallacy. For
example, Helmers et al.7 recently performed an uncontrolled
health-economic study and concluded that ‘‘VNS is associated with
decreased resource utilization and epilepsy-related clinical events
and net cost savings after 1.5 years’’. However, no such associations
can be established in the absence of a control group.
Third, in the VNS literature efﬁcacy is often mixed-up with
clinical effectiveness. Many authors, like Garcı´a-Navarrete et al.,
actually want to recommend VNS for clinical use when they argue
for the ‘‘efﬁcacy’’ of VNS. However, efﬁcacy of VNS has been shown
in two pre-marketing studies.4,5 In these double-blind randomized
controlled trials patients receiving ‘‘true’’ VNS were compared to
patients receiving sham VNS (i.e. low on/off time ratio condition)
to identify the speciﬁc effect of electrically stimulating the vagus in
contrast to the (placebo) effect of only implanting a medical device.
However, while proving efﬁcacy is certainly an essential prerequi-
site for clinical effectiveness it is by no means sufﬁcient. As VNS
therapy is an add-on to best drug treatment (BDT), the clinical
effectiveness of VNS must obviously be shown in terms of
therapeutic beneﬁts which can be achieved by adding VNS to
BDT as compared to not adding VNS. To the best of my knowledge,
only Sherman et al. published a small but controlled study on the
seizure outcome in pediatric patients under BDT plus VNS as
compared to BDT only.6 These authors found no speciﬁc beneﬁts of
adding VNS to BDT.
What makes matters worse is that the majority of systematic
reviews on VNS in the treatment of epilepsies have drawn similarly
positive conclusions about the ‘‘efﬁcacy’’ (read: clinical effective-
ness) instead of unambiguously stating the rather embarrassing
lack of adequately controlled studies. For example, Connor et al.1
recently concluded that ‘‘[v]agal nerve stimulation is a safe and
effective alternative for adult and pediatric populations with
epilepsy refractory to medical and other surgical management’’.
Again, there is no evidence supporting this conclusion and thevier Ltd. All rights reserved.
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arguable whether an implanted medical device which has to be
switched off or explanted in more than 10% of the patients should
be classiﬁed as safe.
In the absence of adequately controlled studies, I suggest using
the data from Callaghan et al.8 as a kind of interim control measure
for the effects of VNS. This suggestion could also be applied to other
innovative non-pharmacological add-on treatments which are
currently explored without adequate control conditions (e.g. deep
brain stimulation, DBS). Callaghan et al. followed a large sample of
therapy refractory non-surgical patients (i.e. eligible candidates for
VNS/DBS) over several years and reported surprisingly good
outcomes of BDT, i.e. ﬂexible lege artis drug treatment. For
example, the annual rate of patients who became seizure-free was
about 5%. Thus, even in severe epilepsy, substantial improvement
due to spontaneous remission, new drugs or more effective drug
combinations remains possible and the efﬁcacy of BDT should not
be underestimated.
Unfortunately, the mean therapeutic changes occurring
during VNS treatment (i.e. 3–5% of patients achieving seizure
cessation, 40–50% experiencing a greater than 50% improve-
ment in seizure frequency1) remain slightly below the effects of
BDT reported by Callaghan et al.8 However, Garcı´a-Navarrete
et al.2 and the authors of so many single-arm studies on VNS do
not consider the possibility that their improved VNS patients
might have been even better off without implantation. Most
pertinently, we do not know whether keeping drug regimens
stable over months and years for an unbiased evaluation of
VNS prevents VNS patients from utilizing the full potential of
state-of-the-art BDT.
To be honest, given the current outcome data on BDT plus VNS
and BDT only, I am not particularly hopefully that future studies
will reliably show the kind of sustained additional therapeutic
effects of adding VNS to BDT which could more than compensate
for the costs, risks, diagnostic limitations, and side-effects
associated with VNS. Fifteen years after approval, we are facing
the possibility that adding VNS to BDT is not actually associated
with any clinically relevant therapeutic beneﬁt for the patients
(despite conﬁrmed efﬁcacy). As the necessary studies on thera-
peutic superiority are still missing and the clinical effectiveness of
add-on VNS over BDT has not been shown so far, the recommen-
dation of VNS to patients is currently not supported by appropriate
evidence.
I know that many epileptologists can report unexpected
therapeutic improvements in individual patients after VNS
implantation. However, this is no scientiﬁc way of establishing
clinical effectiveness. Otherwise, low-cost therapies like homeop-
athy and acupuncture must also be approved and reimbursedbased on anecdotal reports of intriguing ‘‘healings’’. Patients
certainly deserve evidence-based treatments, especially the most
severely affected among them. As non-efﬁcacy can never be
empirically proven for logical reasons, positive evidence from
adequate studies is essential for the acceptance of therapeutic
efﬁcacy and clinical effectiveness.
The end of the VNS story has not yet been written but it already
seems to provide good reasons to re-consider the established
procedures of scientiﬁc (i.e. independent and critical) therapy
evaluation and approval in our ﬁeld. I generally suggest that single-
arm studies of a newly approved innovative treatment should only
be accepted for publication shortly after approval. Such studies may
conﬁrm and document the clinical feasibility of the new treatment.
However, one or two years after approval, only adequately
controlled studies should be accepted for review and publication
to avoid logical fallacies, causal misattribution and the suggestive
mix-up of therapeutic efﬁcacy and clinical effectiveness.
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